Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function

Journal of Neurosurgery

Volumn 88, Issue 3, 1998, Pages 535-540

  Dorigo, Oliver ^a,b   Turla, Sally T ^a   Lebedeva, Svetlana ^a   Gjerset, Ruth A ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; Glioblastoma multiforme; In vivo model; p53; Therapy sensitization

Indexed keywords

CISPLATIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DNA TRANSFECTION; DRUG EFFICACY; FEMALE; GENE TRANSFER; GLIOBLASTOMA; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT;

EID: 0031894340     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1998.88.3.0535     Document Type: Article

References (44)

1. Anker L, Ohgaki H, Ludeke BI, et al: p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982-987, 1993
2. Asai A, Miyagi Y, Sugiyama A, et al: Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19:259-268, 1994
3. Badie B, Drazan KE, Kramer MH, et al: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 17:209-216, 1995
4. Bakalkin G, Selivanova G, Yakovleva T, et al: p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucl Acids Res 23: 362-369, 1995
5. Bigner DD, Bigner SH, Pontén J, et al: Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201-209, 1981
6. Bigner SH, Mark J, Bigner DD: Cytogenetics of human brain tumors. Cancer Genet Cytogenet 47:141-154, 1990
7. Chandler KL, Prados MD, Malec M, et al: Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993
8. Chen X, Ko LJ, Jayaraman L, et al: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response to tumor cells. Genes Dev 10:2438-2451, 1996
9. Choucair AK, Levin VA, Gutin PH, et al: Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654-658, 1986
10. Chung R, Whaley J, Kley N, et al: TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chrom Cancer 3:323-331, 1991
11. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
12. Crook T, Fisher C, Vousden KH: Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol 65:505-510, 1991
13. Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996
14. Fleiss JL: Statistical Methods for Rates and Proportions. New York: Wiley, 1981
15. Frankel RH, Bayona W, Koslow M, et al: p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52:1427-1433, 1992
16. Fugiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
17. Gallardo D, Drazan KE, McBride WH: Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radio-sensitivity. Cancer Res 56:4891-4893, 1996
18. Gjerset RA, Turla ST, Sobol RE, et al: Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285, 1995
19. Goh HS, Yao J, Smith DR: p53 point mutation and survival in 13 colorectal cancer patients. Cancer Res 55:5217-5221, 1995
20. Iwadate Y, Fujimoto S, Tagawa M, et al: Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69:236-240, 1996
21. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
22. Kern SE, Pietenpol JA, Thiagalingham S, et al: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992
23. Kimler BF: The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions. J Neurooncol 20:103-109, 1994
24. Kornblith PK, Welch WC, Bradley MK: The future of therapy for glioblastoma. Surg Neurol 39:538-543, 1993
25. Kruse CA, Schiltz PM, Bellgrau D, et al: Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 19:161-168, 1994
26. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992
27. Lee S, Elenbaas B, Levine A, et al: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020, 1995
28. Levine BS, Henry MC, Port CD, et al: Nephrotoxic potential of cis-diaminedichloroplatinum and four analogs in male Fischer 344 rats. J Natl Cancer Inst 67:201-206, 1981
29. Levine VA, Sheline GE, Gutlin PH: Neoplasms of the central nervous system, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1989, pp 1557-1611
30. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092-1096, 1993
31. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21, 1994
32. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
33. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
34. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 350:1233-1238, 1990
35. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694, 1984
36. Nabeya Y, Loganzo F Jr, Maslak P, et al: The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 64:37-46, 1995
37. Netsky MG, August B, Fowler W: The longevity of patients with glioblastoma multiforme. J Neurosurg 7:261-269, 1950
38. Rose WC, Shurig JE: Preclinical antitumor and toxicologic profile of carboplatinum. Cancer Treat Rev 12 (Suppl A):1-19, 1985
39. Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042, 1995
40. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. New York: Cold Spring Harbor Press, 1989
41. Schmidek HH, Nielsen SL, Schiller AL, et al: Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 34:335-340, 1971
42. Siddik ZH, Boxall FE, Harrap KR: Haematological toxicity of carboplatin in rats. Br J Cancer 55:375-379, 1987
43. Sidransky D, Mikkelsen T, Schwechheimer K, et al: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846-847, 1993
44. von Deimling A, Eibl RH, Ohgaki H, et al: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52:2987-2990, 1992